News

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.
Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.
Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...
Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis ...
An international team of researchers, including experts from the University of Adelaide, has found genomic testing and ...
USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH ...
David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...
The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...